Skip to main content
SpringerPlus

Table 3 Objective tumor response

From: Comparison of platinum combination re-challenge therapy and docetaxel monotherapy in non-small cell lung cancer patients previously treated with platinum-based chemoradiotherapy

 

Platinum combination therapy (n = 24) n (%)

Docetaxel monotherapy (n = 61) n (%)

p value*

Complete response

0 (0)

1 (1.6)

0.30

Partial response

4 (16.7)

3 (4.9)

 

Stable disease

10 (41.7)

31 (50.8)

 

Progressive disease

9 (37.5)

24 (39.3)

 

Not evaluable

1 (4.1)

2 (3.3)

 

Response rate (%)

16.7

6.6

0.09

Disease control ratea (%)

58.3

57.4

0.82

  1. *Fisher’s exact test.
  2. aComplete response + partial response + stable disease.
Back to article page